SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-24-008352
Filing Date
2024-02-16
Accepted
2024-02-16 16:03:00
Documents
18
Period of Report
2024-02-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20021883_8k.htm   iXBRL 8-K 39035
2 EXHIBIT 10.1 ef20021883_ex10-1.htm EX-10.1 110567
3 EXHIBIT 10.2 ef20021883_ex10-2.htm EX-10.2 17056
4 EXHIBIT 99.1 ef20021883_ex99-1.htm EX-99.1 21631
8 image0.jpg GRAPHIC 6484
  Complete submission text file 0001140361-24-008352.txt   371013

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ocup-20240212.xsd EX-101.SCH 3866
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE ocup-20240212_lab.xml EX-101.LAB 22547
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ocup-20240212_pre.xml EX-101.PRE 16045
20 EXTRACTED XBRL INSTANCE DOCUMENT ef20021883_8k_htm.xml XML 4087
Mailing Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335
Business Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335 248-681-9815
Ocuphire Pharma, Inc. (Filer) CIK: 0001228627 (see all company filings)

IRS No.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 24648261
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)